Skip to content
RallyBio News

RallyBio announces clinical proof of concept for RLYB211, an anti-HPA-1a antibody for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).

Rallybio, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that clinical proof of concept has been established in the ongoing Phase 1/2 study of RLYB211. 

Back To Top